Expand All
Collapse All

Active ingredient

Orlistat 120 mg


Obesity management.

Dosage and Administration

The recommended dose of Quick-Slim is one 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal).


  • In patients with chronic malabsorption syndrome or  cholestasis.
  • In patients with known hypersensitivity to orlistat or to any component of this product.

Side effects

Gastrointestinal (GI) symptoms were the most commonly observed treatment-emergent adverse events associated with the use of orlistat in the seven double-blind, placebo-controlled clinical trials and are primarily a manifestation of the mechanism of action. (Commonly observed is defined as an incidence of ≥ 5% and an incidence in the orlistat 120 mg group that is at least twice that of placebo).

Drug Interaction

Drug-drug interaction studies indicate that Quick-Slim had no effect on pharmacokinetics and/or pharmacodynamics of alcohol, digoxin, glyburide, nifedipine (extended-release tablets), oral contraceptives, phenytoin, pravastatin, or warfarin. Alcohol did not affect the pharmacodynamics of orlistat.

Pregnancy and Lactation

  • Teratogenic Effects: Pregnancy Category B. 
  • Teratogenicity studies were conducted in rats and rabbits at doses up to 800 mg/kg/day.
  • Neither study showed embryo toxicity or teratogenicity. This dose is 23 and 47 times the daily human dose calculated on
    a body surface area (mg/m2) basis for rats and rabbits, respectively.
  • The incidence of dilated cerebral ventricles was increased in the mid- and high-dose groups of the rat teratology study.
  • These doses were 6 and 23 times the daily human dose calculated on a body surface area (mg/m2) basis for the mid- and high-dose levels, respectively. This finding was not reproduced in two additional rat teratology studies at similar doses.
  • There are no adequate and well-controlled studies of orlistat in pregnant women. Because animal reproductive studies are not always predictive of human response, orlistat is not recommended for use during pregnancy.
  • Nursing Mothers It is not known if orlistat is secreted in human milk. Therefore, Quick-Slim should not be taken by nursing women.

Warning and Precaution

  • Organic causes of obesity (eg, hypothyroidism) should be excluded before prescribing Quick-Slim.
  • Preliminary data from a Quick-Slim and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when Quick-Slim was co-administered with cyclosporine.
  • Therefore, Quick-Slim and cyclosporine should not be co-administered. To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 2 hours before or after Quick-Slim in patients taking both drugs. In addition, in those patients whose cyclosporine levels are being measured, more frequent monitoring should be considered.
  • Patients should be advised to adhere to dietary guidelines (see dosage and administration). Gastrointestinal events (see side effects) may increase when Quick-Slim is taken with a diet high in fat (>30% total daily calories from fat). The daily intake of fat should be distributed over three main meals.
  • If Quick-Slim is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases.
  • Patients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition because Quick-Slim has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene (see dosage and administration)
  • In addition, the levels of vitamin D and beta-carotene may be low in obese patients compared with non-obese subjects.
    The supplement should be taken once a day at least 2 hours before or after the administration of Quick-Slim, such as at bedtime.

Package and Storage

  • Package: Carton box containing 3 strips each of 10 capsule & insert leaflet.
  • ​Store at temperature not exceeding 30°C

Mother Company

Manufactured by Marcyrl